Forschungsseminar: Vortrag von Prof. Dr. Georgios Imanidis

Colonic delivery is indicated for treating disorders of the large intestine (e.g., inflammatory bowel disease) and/or dysbiosis of the microbiome.  To achieve colonic delivery by per-oral administration, dosage form technology is required that makes possible unscathed passage through the upper gastrointestinal tract and release of the drug payload in the large intestine.  The School of Life Sciences developed a dual control release technology of tablets that was demonstrated in vitro and in preclinical studies to provide quantitative colonic delivery.  Now this technology is tested with a scintigraphy trial in man. Colonic delivery is indicated for treating disorders of the large intestine (e.g., inflammatory bowel disease) and/or dysbiosis of the microbiome.